Summary
Medical biotechnology applies molecular and cellular techniques to develop diagnostics, therapeutics and preventive measures that transform patient care. Central strategies include recombinant production of therapeutic proteins and antibodies, gene-based vaccines and genome editing to correct inherited mutations. Delivery platforms such as lipid nanoparticles and polymeric carriers enhance nucleic acid stability and tissue specificity, while biomaterial scaffolds and microRNA modulators enable targeted repair and regeneration. Liquid biopsies analysing cell-free nucleic acids offer non-invasive disease monitoring, and CRISPR-based systems permit precise genetic interventions. By integrating advances from genomics, proteomics and nanotechnology, medical biotechnology accelerates translation from molecular insight to clinical application across oncology, infectious disease, inherited disorders and regenerative medicine.
Research from Nature Portfolio
A novel algorithmic design of mRNA constructs simultaneously optimises codon usage and secondary structure, yielding vaccine sequences with markedly prolonged half-life and enhanced protein expression. In preclinical models the optimised mRNAs elicited antibody titres up to 128-fold higher than standard codon-optimised controls and extended serum residence by two orders of magnitude. Personalized mRNA–lipoplex vaccines encoding patient-specific tumour neoantigens have advanced into phase I trials in pancreatic ductal adenocarcinoma, where combined adjuvant administration induced de novo polyfunctional CD8⁺ T cell responses against multiple neoepitopes and correlated with sustained recurrence-free survival. In obstetric screening, longitudinal profiling of circulating cell-free RNA has defined an eighteen-gene panel that predicts pre-eclampsia risk in early gestation, outperforming established clinical factors and opening avenues for non-invasive early intervention.
Topic trend for the past 5 years
The graph below shows the article count in Nature Index journals for medical biotechnology.
* The ‘Current Index’ represents data for a 12-month rolling window, the current window is 1 May 2025 - 30 April 2026.
Technical terms
mRNA vaccine: A vaccine that delivers messenger RNA encoding an antigen, enabling in situ translation and immune activation against the target protein.
Neoantigen: A tumour-specific peptide arising from somatic mutations, not present in normal tissues, used to direct personalised T cell immunity.
Cell-free RNA (cfRNA): Extracellular RNA fragments in plasma reflecting gene expression of foetal, placental or tumour cells, employed as non-invasive biomarkers.
Lipid nanoparticle: A self-assembling vesicle composed of ionisable lipids, cholesterol and PEGylated lipids for encapsulation and targeted delivery of nucleic acids.
Elastin-like polypeptide (ELP): A genetically encoded biopolymer exhibiting reversible inverse temperature transition, used to create depot-forming protein therapeutics.
MicroRNA inhibitor (antagomiR): A chemically modified oligonucleotide designed to bind and silence endogenous microRNAs, modulating gene expression post-transcriptionally.
Notable articles in medical biotechnology
- Algorithm for optimized mRNA design improves stability and immunogenicity. Nature (2023).
- Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature (2023).
- Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature (2022).
- A Multifunctional Scaffold for Bone Infection Treatment by Delivery of microRNA Therapeutics Combined With Antimicrobial Nanoparticles. Advanced Materials (2023).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Research
Position of Medical Biotechnology in Nature Index by Count
Leading institutions
| Institution | Count | Share |
|---|---|---|
| Chinese Academy of Sciences (CAS) | 204 | 54.66 |
| Sichuan University (SCU) | 66 | 42.18 |
| Zhejiang University (ZJU) | 76 | 39.08 |
| Peking University (PKU) | 88 | 33.17 |
| Shanghai Jiao Tong University (SJTU) | 82 | 30.32 |
| People's Liberation Army (PLA) | 84 | 22.42 |
| Harvard University | 67 | 21.61 |
| Fudan University | 63 | 20.45 |
| University of Chinese Academy of Sciences (UCAS) | 92 | 20.03 |
| University of Pennsylvania (Penn) | 46 | 19.79 |
Collaboration
Top 5 leading collaborators in Medical Biotechnology
Collaborating institutions
Note: Hover over the bars to view details about each institution's Share.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.